RxDoctor Payments Data

Sandra Lloyd

Physician Assistant · Lincoln, NENPI 1285684647

Payments from drug & device makers

$974in general payments, 2019–2025

Across 28 payments — averaging $34.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$156
  • Teleflex LLC$142
  • Fresenius USA Marketing, Inc.$118
  • Aurinia Pharma U.S., Inc.$107
  • GSK$77
  • AstraZeneca$77
  • plus $297 from 8 others

What the payments were for

  • Food & beverage$974100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$974 in reported general payments places this provider in the 70th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$36,422
Medicare patients
249
Services billed
792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$15,108
MyrbetriqMirabegron15$6,616
SymbicortBudesonide/Formoterol Fumarate13$3,094
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen42$1,053
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,049
Potassium Chloride16$979
Albuterol Sulfate HfaAlbuterol Sulfate30$862
Pantoprazole Sodium47$502
Metformin Hcl21$498
Pregabalin16$451
Celecoxib20$391
Omeprazole15$336
Nystatin11$327
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$279
Hydrochlorothiazide41$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$156$15,10817 claims
AstraZenecaSymbicort$77$3,09413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →